Clinical trial
Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind…
NCT00148850 · French National Agency for Research on AIDS and Viral Hepatitis, Other · Terminated
Key facts
| NCT number | NCT00148850 |
|---|---|
| Title | Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients |
| Official title | A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study |
| Lead sponsor | French National Agency for Research on AIDS and Viral Hepatitis, Other |
| Collaborators | Takeda Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV-Associated Lipodystrophy Syndrome, HIV Infections |
| Intervention type | Drug |
| Interventions | Pioglitazone |
| Enrollment | 130 |
| Start date | Feb 1, 2003 |
| Completion | Oct 1, 2004 |
| First posted | Sep 8, 2005 |
| Last update posted | Oct 20, 2005 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: